S
Stephanie Lheureux
Researcher at Princess Margaret Cancer Centre
Publications - 86
Citations - 3272
Stephanie Lheureux is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 20, co-authored 33 publications receiving 1736 citations. Previous affiliations of Stephanie Lheureux include University Health Network & University of Caen Lower Normandy.
Papers
More filters
Journal ArticleDOI
Epithelial Ovarian Cancer
TL;DR: Urgent progress is needed to develop evidence and consensus-based treatment guidelines for each subgroup, and requires close international cooperation in conducting clinical trials through academic research groups such as the Gynecologic Cancer Intergroup.
Journal ArticleDOI
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
TL;DR: To improve survival in this aggressive disease, access to appropriate evidence‐based care is requisite and individualized precision medicine will require prioritizing clinical trials of innovative treatments and refining predictive biomarkers that will enable selection of patients who would benefit from chemotherapy, targeted agents, or immunotherapy.
Journal ArticleDOI
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V. Bratman,Scott V. Bratman,S. Y. Cindy Yang,S. Y. Cindy Yang,Marco A. J. Iafolla,Marco A. J. Iafolla,Zhihui Liu,Zhihui Liu,Aaron R. Hansen,Aaron R. Hansen,Philippe L. Bedard,Philippe L. Bedard,Stephanie Lheureux,Stephanie Lheureux,Anna Spreafico,Anna Spreafico,Albiruni Ryan Abdul Razak,Albiruni Ryan Abdul Razak,Svetlana Shchegrova,Maggie C. Louie,Paul Billings,Bernhard Zimmermann,Himanshu Sethi,Alexey Aleshin,Dax Torti,Kayla Marsh,Jenna Eagles,Iulia Cirlan,Youstina Hanna,Derek L. Clouthier,Scott C. Lien,Scott C. Lien,Pamela S. Ohashi,Pamela S. Ohashi,Wei Xu,Wei Xu,Lillian L. Siu,Lillian L. Siu,Trevor J. Pugh,Trevor J. Pugh +39 more
TL;DR: The potential for broad clinical utility of ctDNA-based surveillance in patients treated with ICB is demonstrated, and 12 patients with ct DNA clearance during treatment were alive with median 25 months follow up.
Journal ArticleDOI
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
William P. Tew,Christina Lacchetti,Annie Ellis,Kathleen Maxian,Susana Banerjee,Michael A. Bookman,Monica Brown Jones,Jung-Min Lee,Stephanie Lheureux,Joyce F. Liu,Kathleen N. Moore,Carolyn Y. Muller,Patricia Rodriguez,Christine Walsh,Shannon N. Westin,Elise C. Kohn +15 more
TL;DR: PARPis are not recommended for use in combination with chemotherapy, other targeted agents, or immune-oncology agents in the recurrent setting outside the context of a clinical trial, and data to support reuse of PARPis in any setting are needed.
Journal ArticleDOI
Treatment strategies for endometrial cancer: current practice and perspective.
TL;DR: The precise role and sequence of conventional and targeted therapies, including immunotherapy, will require careful attention to the design of clinical trials with translational emphasis to allow the discovery, validation, and implementation of predictive biomarkers into clinical care.